Poor
Not Aligned
Patient Risk:
High
Summary
Many safety and side-effect claims are not supported by the provided prescribing information; several interaction/clinical-risk claims (notably serotonin syndrome and “cardiovascular events with antidepressants”) are unsupported, and the stated common side effects (abdominal pain/diarrhea/nausea/vomiting/headache) are not listed as common in the provided label excerpts.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication.
Not explicitly supported by the provided excerpts.
Vascepa contains icosapent ethyl (ethyl ester of omega-3 fatty acid EPA).
Drug/Active ingredient details and Label text: 5.2 describes ethyl esters of EPA obtained from fish oil.
Vascepa works by reducing hepatic very low-density lipoprotein (VLDL) triglyceride synthesis and/or secretion and enhances TG clearance from circulating VLDL particles.
Label 12.1 Mechanism of Action.
Vascepa reduces triglyceride levels in the blood.
Label 12.2 Pharmacodynamics: reduced median TG vs placebo; Label 14.2: reduced median TG from baseline relative to placebo.
Vascepa is associated with an increased risk of bleeding.
Label 5.3 Bleeding.
Vascepa bleeding risk is greater with concomitant antithrombotic medications such as warfarin.
Label 5.3: incidence of bleeding greater with concomitant antithrombotic medications including warfarin; Label 7.1 also instructs to monitor with anticoagulants/antiplatelet agents.
Healthcare providers should monitor patients taking both Vascepa and antidepressants for potential side effects.
General monitoring with concomitant anticoagulants/antiplatelet agents is supported (Label 7.1), but “antidepressants” specifically is not supported in the provided excerpts.
Unsupported Statements
Vascepa is primarily used to treat high triglyceride levels.
Provided label excerpts describe specific indications (adjunct to maximally tolerated statin to reduce risk of MI/stroke/etc. in adults with elevated TG, and adjunct to diet to reduce TG in severe hypertriglyceridemia), not that it is “primarily used” solely to treat high TG.
High triglyceride levels can increase the risk of heart disease and stroke.
The provided label excerpts do not state this relationship.
Vascepa works by inhibiting the production of triglycerides in the liver.
Label 12.1 supports multiple mechanisms including decreased lipogenesis in the liver and inhibition of DGAT, but the specific phrasing “inhibiting the production of triglycerides in the liver” is not directly stated in the excerpts.
Common side effects of Vascepa may include abdominal pain, diarrhea, nausea, vomiting, headache.
Label 6.1 lists common adverse reactions as musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation; other listed symptoms are not supported as “common” in the provided excerpts.
Vascepa may increase the risk of bleeding when combined with antidepressants.
Provided label excerpts discuss bleeding risk with concomitant anticoagulants/antiplatelet agents (including warfarin) but do not mention antidepressants.
The increased bleeding risk with Vascepa and antidepressants is particularly noted with antidepressants that affect platelet function.
Not supported in the provided label excerpts.
Selective serotonin reuptake inhibitors (SSRIs) are examples of antidepressants that affect platelet function.
Not addressed in the provided label excerpts.
The combination of Vascepa and antidepressants may increase the risk of serotonin syndrome.
Serotonin syndrome is not mentioned in the provided label excerpts.
Serotonin syndrome is a potentially life-threatening condition characterized by excessive levels of serotonin in the body.
Not mentioned in the provided label excerpts.
Vascepa may increase the risk of cardiovascular events, such as heart attack and stroke, when combined with antidepressants.
The provided label excerpts address cardiovascular event risk reduction with Vascepa in specified populations; no antidepressant combination risk is stated.
The increased cardiovascular event risk with Vascepa and antidepressants is particularly noted with antidepressants that affect blood pressure or heart rate.
Not supported in the provided label excerpts.
Vascepa may increase the risk of serotonin syndrome when combined with SSRIs and MAOIs.
Serotonin syndrome and these antidepressant class interactions are not mentioned in the provided label excerpts.
Fluoxetine is an example of an SSRI; Sertraline is an example of an SSRI; Phenelzine is an example of an MAOI; Tranylcypromine is an example of an MAOI.
Not supported or addressed in the provided label excerpts.
A study in the Journal of Clinical Psychopharmacology states that the combination of omega-3 fatty acids and antidepressants may be associated with an increased risk of bleeding and serotonin syndrome.
Not supported by the provided prescribing information excerpts.
A case report in the Journal of Clinical Psychopharmacology describes a patient who developed serotonin syndrome after taking Vascepa and an SSRI.
Not supported by the provided prescribing information excerpts.
Informing a healthcare provider about side effects and adjusting the medication regimen may be necessary when experiencing side effects while taking both Vascepa and antidepressants.
The label excerpt does not address antidepressant coadministration or serotonin syndrome-type management.
Contradictions
Low
AI Statement
Vascepa contains icosapent ethyl, a highly purified form of omega-3 fatty acid.
Label Reference
Provided excerpts specify ethyl esters of EPA obtained from fish oil (5.2) but do not state “highly purified.”
Low
AI Statement
The daily dose of Vascepa (not stated in AI claims) is unsupported/contradiction?
Label Reference
Important Omissions
No mention of the actual FDA-approved indications (adjunct to maximally tolerated statin therapy to reduce risk of MI/stroke/coronary revascularization/unstable angina hospitalization in adults with elevated TG; and adjunct to diet to reduce TG in severe hypertriglyceridemia).
Importance:
Moderate
No dosing instructions from the label (4 grams/day in specified capsule regimens with food; swallow capsules whole).
Importance:
Moderate
No supported warnings/precautions from the provided excerpts besides bleeding (e.g., atrial fibrillation/flutter risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims introduce interaction risks (serotonin syndrome; antidepressants causing bleeding/cardiovascular event risk) and common side effects (abdominal pain/diarrhea/nausea/vomiting/headache) that are not supported by the provided labeling excerpts, which could mislead monitoring expectations and patient counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported antidepressant-related interaction and serotonin syndrome claims; unsupported “common side effects” not listed in the provided label excerpts.
Suggested Improvement
Restrict interaction/safety statements to those supported by the provided label (bleeding risk with anticoagulants/antiplatelet agents including warfarin; monitor for bleeding per label 7.1) and align adverse reaction listings to those specified as common in label 6.1.